Maurer-Spurej E - Search Results

1

Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100.

Madsen EH, Schmidt EB, Maurer-Spurej E, Kristensen SR. Madsen EH, et al. Platelets. 2008 Aug;19(5):335-41. doi: 10.1080/09537100801989857. Platelets. 2008. PMID: 18791939 Clinical Trial.

2

Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention.

Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Madsen EH, et al. Clin Chem. 2010 May;56(5):839-47. doi: 10.1373/clinchem.2009.137471. Epub 2010 Mar 11. Clin Chem. 2010. PMID: 20224050 Free article.

3

The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study.

Saw J, Madsen EH, Chan S, Maurer-Spurej E. Saw J, et al. J Am Coll Cardiol. 2008 Dec 2;52(23):1826-1833. doi: 10.1016/j.jacc.2008.08.047. J Am Coll Cardiol. 2008. PMID: 19038679 Free article. Clinical Trial.

4

The value of proteomics for the diagnosis of a platelet-related bleeding disorder.

Maurer-Spurej E, Kahr WH, Carter CJ, Pittendreigh C, Cameron M, Cyr TD. Maurer-Spurej E, et al. Platelets. 2008 Aug;19(5):342-51. doi: 10.1080/09537100802010547. Platelets. 2008. PMID: 18791940

5

Platelet aggregation is not initiated by platelet shape change.

Maurer-Spurej E, Devine DV. Maurer-Spurej E, et al. Lab Invest. 2001 Nov;81(11):1517-25. doi: 10.1038/labinvest.3780365. Lab Invest. 2001. PMID: 11706059

6

Quebec platelet disorder: features, pathogenesis and treatment.

Diamandis M, Veljkovic DK, Maurer-Spurej E, Rivard GE, Hayward CP. Diamandis M, et al. Blood Coagul Fibrinolysis. 2008 Mar;19(2):109-19. doi: 10.1097/MBC.0b013e3282f41e3e. Blood Coagul Fibrinolysis. 2008. PMID: 18277131 Review.

7

Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies.

Maurer-Spurej E, Labrie A, Pittendreigh C, Chipperfield K, Smith C, Heddle N, Liu Y, Yi QL, Barnett M. Maurer-Spurej E, et al. Transfusion. 2009 Nov;49(11):2276-84. doi: 10.1111/j.1537-2995.2009.02302.x. Transfusion. 2009. PMID: 19903289

8

Routine Screening Method for Microparticles in Platelet Transfusions.

Millar D, Murphy L, Labrie A, Maurer-Spurej E. Millar D, et al. Among authors: maurer spurej e. J Vis Exp. 2018 Jan 31;(131):56893. doi: 10.3791/56893. J Vis Exp. 2018. PMID: 29443045 Free PMC article.

9

Microparticle detection to guide platelet management for the reduction of platelet refractoriness in children - A study proposal.

Kanzler P, Mahoney A, Leitner G, Witt V, Maurer-Spurej E. Kanzler P, et al. Among authors: maurer spurej e. Transfus Apher Sci. 2017 Feb;56(1):39-44. doi: 10.1016/j.transci.2016.12.016. Epub 2016 Dec 29. Transfus Apher Sci. 2017. PMID: 28089410

10

Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress.

Maurer-Spurej E, Larsen R, Labrie A, Heaton A, Chipperfield K. Maurer-Spurej E, et al. Transfus Apher Sci. 2016 Aug;55(1):35-43. doi: 10.1016/j.transci.2016.07.010. Epub 2016 Jul 18. Transfus Apher Sci. 2016. PMID: 27470708 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results